Q1 2025 Earnings Forecast for Incyte Co. (NASDAQ:INCY) Issued By William Blair

Incyte Co. (NASDAQ:INCY) – Research analysts at William Blair raised their Q1 2025 earnings estimates for shares of Incyte in a note issued to investors on Tuesday, April 23rd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $0.90 for the quarter, up from their prior estimate of $0.71. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $3.85 per share.

INCY has been the subject of a number of other reports. Citigroup dropped their price target on shares of Incyte from $82.00 to $81.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $65.00 target price on shares of Incyte in a research note on Monday, March 25th. Truist Financial decreased their price target on Incyte from $91.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Oppenheimer cut their price objective on Incyte from $92.00 to $84.00 and set an “outperform” rating on the stock in a research report on Wednesday. Finally, BMO Capital Markets lifted their target price on Incyte from $58.00 to $64.00 and gave the stock a “market perform” rating in a research report on Wednesday, February 14th. Nine investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $75.50.

Incyte Stock Down 1.1 %

NASDAQ INCY opened at $51.18 on Thursday. Incyte has a 52 week low of $50.27 and a 52 week high of $75.74. The firm has a market capitalization of $11.49 billion, a price-to-earnings ratio of 19.31, a PEG ratio of 1.19 and a beta of 0.65. The company has a quick ratio of 3.36, a current ratio of 3.55 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $56.90 and a two-hundred day moving average of $57.73.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Incyte had a return on equity of 12.56% and a net margin of 16.17%. Incyte’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.44 EPS.

Hedge Funds Weigh In On Incyte

A number of hedge funds and other institutional investors have recently modified their holdings of INCY. Fisher Asset Management LLC boosted its position in Incyte by 0.4% during the fourth quarter. Fisher Asset Management LLC now owns 44,169 shares of the biopharmaceutical company’s stock valued at $2,773,000 after purchasing an additional 187 shares in the last quarter. 180 Wealth Advisors LLC lifted its position in shares of Incyte by 4.5% during the first quarter. 180 Wealth Advisors LLC now owns 4,764 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 204 shares during the last quarter. Berger Financial Group Inc boosted its holdings in shares of Incyte by 0.4% in the 4th quarter. Berger Financial Group Inc now owns 60,468 shares of the biopharmaceutical company’s stock valued at $3,797,000 after buying an additional 212 shares in the last quarter. Allworth Financial LP grew its position in shares of Incyte by 40.0% in the 4th quarter. Allworth Financial LP now owns 802 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 229 shares during the last quarter. Finally, Grandfield & Dodd LLC raised its stake in shares of Incyte by 1.8% during the 4th quarter. Grandfield & Dodd LLC now owns 18,390 shares of the biopharmaceutical company’s stock worth $1,155,000 after acquiring an additional 319 shares in the last quarter. 96.97% of the stock is currently owned by institutional investors.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.